Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials.

作者: Tayebeh Rezaei , Saeed Khalili , Behzad Baradaran , Jafar Mosafer , Sarah Rezaei

DOI: 10.1016/J.JCONREL.2019.10.045

关键词:

摘要: According to WHO (World Health Organization) reports, more than 770,000 people died from HIV and almost 1.7 million becoming newly infected in the worldwide 2018. Therefore, many attempts should be done produce a forceful vaccine control AIDS. DNA-based vaccines have been investigated for vaccination by researches during recent 20 years. The DNA are novel approach induction of both type immune responses (cellular humoral) host cells advantages including high stability, fast easy fabrication absence severe side effects when compared with other methods. Recent studies focused on design, use adjuvants as promising strategy increased level responses, delivery approaches viral non-viral methods vector design different antigens virus. In this review, we outlined aforementioned advances vaccines. Then described future trends clinical trials strong even healthy volunteers potential developments prevention HIV.

参考文章(161)
Robert Julian Binder, Functions of Heat Shock Proteins in Pathways of the Innate and Adaptive Immune System Journal of Immunology. ,vol. 193, pp. 5765- 5771 ,(2014) , 10.4049/JIMMUNOL.1401417
D. A. Donahue, B. D. Kuhl, R. D. Sloan, M. A. Wainberg, The viral protein Tat can inhibit the establishment of HIV-1 latency. Journal of Virology. ,vol. 86, pp. 3253- 3263 ,(2012) , 10.1128/JVI.06648-11
Said Aboud, Charlotta Nilsson, Katarina Karlén, Mary Marovich, Britta Wahren, Eric Sandström, Hans Gaines, Gunnel Biberfeld, Karina Godoy-Ramirez, Strong HIV-specific CD4+ and CD8+ T-lymphocyte proliferative responses in healthy individuals immunized with an HIV-1 DNA vaccine and boosted with recombinant modified vaccinia virus ankara expressing HIV-1 genes. Clinical and Vaccine Immunology. ,vol. 17, pp. 1124- 1131 ,(2010) , 10.1128/CVI.00008-10
Anna-Lise Williamson, Edward P Rybicki, Justification for the inclusion of Gag in HIV vaccine candidates Expert Review of Vaccines. ,vol. 15, pp. 585- 598 ,(2016) , 10.1586/14760584.2016.1129904
Lei Li, Nikolai Petrovsky, Molecular mechanisms for enhanced DNA vaccine immunogenicity Expert Review of Vaccines. ,vol. 15, pp. 313- 329 ,(2016) , 10.1586/14760584.2016.1124762
N Habibzadeh, A Bolhassani, R Vahabpour, SM Sadat, How can Improve DNA Vaccine Modalities as a Therapeutic Approach against HIV Infections? Journal of AIDS & Clinical Research. ,vol. 06, pp. 1- 8 ,(2015) , 10.4172/2155-6113.1000440
Fatemeh Soltani, Hamideh Parhiz, Ahad Mokhtarzadeh, Mohammad Ramezani, Synthetic and Biological Vesicular Nano-Carriers Designed for Gene Delivery. Current Pharmaceutical Design. ,vol. 21, pp. 6214- 6235 ,(2015) , 10.2174/1381612821666151027153410
Ahad Mokhtarzadeh, Abbas Alibakhshi, Hajar Yaghoobi, Maryam Hashemi, Maryam Hejazi, Mohammad Ramezani, Recent advances on biocompatible and biodegradable nanoparticles as gene carriers. Expert Opinion on Biological Therapy. ,vol. 16, pp. 771- 785 ,(2016) , 10.1517/14712598.2016.1169269
Eric Farris, Deborah M Brown, Amanda E Ramer-Tait, Angela K Pannier, Micro- and nanoparticulates for DNA vaccine delivery. Experimental Biology and Medicine. ,vol. 241, pp. 919- 929 ,(2016) , 10.1177/1535370216643771
H Arai, K-Q Xin, K Hamajima, Y Lu, S Watabe, T Takahashi, S Toda, K Okuda, I Kudoh, M Suzuki, K Okuda, 8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine Gene Therapy. ,vol. 7, pp. 694- 702 ,(2000) , 10.1038/SJ.GT.3301145